Last edition
News about "Paola Casarosa"
Phase II data show apecotrep, a first-in-class oral TRPC6 inhibitor, significantly reduced proteinuria in patients with primary FSGS, supporting ongoing Phase III development.
Paola Casarosa | 29/01/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members